Method and composition for treating thrombosis

Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

514 11, 530317, A61K 3800

Patent

active

060178779

ABSTRACT:
The invention provides cyclic peptides which inhibit platelet aggregation without causing prolonged bleeding time. The invention provides RGD or KGD containing peptides which are cyclized and contain hydrophobic amino acids adjacent to the carboxy terminus of the RGD sequence. Peptides of this nature are also provided which contain in addition to the hydrophobic amino acid an adjacent positively charged amino acid. Such peptides have a high affinity for the receptor IIb/IIIa and a low affinity for the fibronectin and vitronectin receptors. Such peptides can be administered in a suitable physiologically acceptable carrier to therapeutically treat thrombosis.

REFERENCES:
patent: 5023233 (1991-06-01), Nutt et al.
patent: 5057604 (1991-10-01), Brown
patent: 5643872 (1997-07-01), Ali et al.
Kopple et al., "Conformations of Arg-Gly-Asp Containing Heterodetic Cyclic Peptides: Solution and Crystal Studies", J. Am. Chem. Soc., 114: 9615-9623, (1992).
Schiller et al., "Synthesis of side-chain to side-chain cyclized peptide analogs on solid supports" Int. J. Peptide Protein Res. 25:171-177 (1985).
Felix et al., "Applications of BOP reagent in solid phase synthesis" Int. J. Peptide Protein Res. 31:231-238 (1988).
Felix et al., "Synthesis, biological activity and conformational analysis of cyclic GRF analogs" Int. J. Peptide Protein Res. 32:441-454 (1988).
Al-Obeidi et al., "Potent and prolonged acting cyclic lactamanalogues of .alpha.-melanotropin: design based on molecular dynamics" J. Med. Chem. 32:2555-2561 (1989).
Pytela et al., "Arginine-Glycine-Aspartic acid adhesion receptors" Methods Enzymol. 144:475-489 (1987).
Lipinska et al., "Fibrinogen heterogeneity in human plasma. Electrophoretic demonstration and characterization of two major fibrinogen components" J. Lab. Clin. Med. 84(4):509-516 (1974).
Yatohgo et al., "Novel purification of vitronectin from human plasma by heparin affinity chromatography" Cell Structure and Function 13:281-292 (1988).
Newman et al., "Quantitation of membrane glycoprotein IIIa on intact human platelets using the monoclonal antibody, AP-3" Blood 65(1):227-232 (1985).
Fitzgerald et al., "A method for purifying the platelet membrane glycoprotein IIb-IIIa complex" Anal. Biochem. 151:169-177 (1985).
Ledford et al., "A comparative study of three methods for the visualization of von Willebrand Factor (vWF) multimers" Thrombosis and Hemostasis 64(4):569-575 (1990).
Born, G.V.R., "Aggregation of blood platelets by adenosine diphosphate and its reversal" Nature 194:927-929 (1962).
Yim and Huffman, "A facile synthesis of .beta.-(S-benzylmercapto)-.beta.,.beta.-cyclopentamethylene-propionic acid" Int. J. Peptide Protein Res. 21:568-570 (1983).
Solar and Schumaker, J. Org. Chem. 31:1996 (1966).
Engvall and Ruoslahti, "Binding of soluble form of fibroblast surface protein, fibronectin, to collagen" Int. J. Cancer 20:1-5 (1977).
Pierschbacher et al., J. Biol. Chem., vol. 262, No. 36 Dec. 25, 1987, pp. 17294-17298.
Cadroy et al., J. Clin. Invest., vol. 84, Sep. 1989, pp. 939-944.
Lam et al., J. Biol. Chem., vol. 262, No. 3, Jan. 25, 1987, pp. 947-950.

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Method and composition for treating thrombosis does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Method and composition for treating thrombosis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method and composition for treating thrombosis will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-2315958

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.